心可舒治疗频发早搏疗效观察(英文)  

Clinical Observation on Effects of Xinkeshu Tablets on Patients with Frequent Premature Beats

作　　者：王美利[1] 胡明明[1] 郑方胜[1] 庄旭娜[1] 季红燕[1] 

机构地区：[1]青岛大学医学院附属医院心内科,山东青岛266003

出　　处：《现代生物医学进展》2011年第19期3756-3759,共4页Progress in Modern Biomedicine

摘　　要：目的:应用心率变异性的方法观察心可舒片对早搏的治疗效果及其影响。方法:将96例频发早搏患者随机分成治疗组(51例)和对照组(45例)。对照组给予倍他乐克缓释片口服,47.5mg/次,1次/日,治疗组在口服倍他乐克缓释片基础上加用心可舒片4片/次,3次/日。在服药前及服药后1个月各行1次动态心电图及普通心电图检查,并进行临床观察。结果:治疗组在消除早搏,改善临床症状方面较对照组明显有效(P<0.05),治疗组较对照组心率变异性改善有明显差异(P<0.05)。结论:心可舒片与倍他乐克合用可有效增加其治疗早搏的作用,同时改善心率变异性和改善倍他乐克引起的窦性心动过缓副作用,有较好的临床疗效。Objective： To investigate the effects of Xinkeshu tablets on patients with frequent premature beats. Methods： Ninety-six patients with frequent premature beats were randomly divided into the experimental group （51cases） and the control group （45cases）, The patients in control group took Betaloc （Astrazenca Ltd.） 47.5mg per day and the patients in the experimental group took Xinkeshu tablets（Shandong Wohua Pharmaceutical Co., Ltd.） 4 tablets three times a day and Betaloc 47.5mg per day. Holter and general electrocardiogram （ECG） checks were lined before taking the medication and a month after taking it respectively, and its clinical therapeutic effects were observed. Results： It is more effective （P〈0.05） in the elimination of prematore beats and the improvement of the clinical symptoms and HRV in the experimental group compared with the control group. Conclusions： The combination of Xinkeshu tablets and Betaloe can effectively increase the role of Betaloc in treating premature beats, while improving heart rate variability and relieving the side effect of sinus bradycardia caused by Betaloc sustained-release tablets.

关 键 词：心可舒 倍他乐克 早搏 心率变异性 

分 类 号：R541.7[医药卫生—心血管疾病]